JP MORGAN/PUT/VERTEX PHARMACEUTICALS/350/0.1/19.07.24 | Delayed Börse Stuttgart 07:36:40 03/07/2024 BST | ||
| 0.008 EUR | -20.00% |
|
| Current month | +14.29% | ||
| 1 month | -71.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 0.008 | -20.00% |
| 02/07/24 | 0.01 | +11.11% |
| 01/07/24 | 0.009 | +28.57% |
| 28/06/24 | 0.007 | +16.67% |
| 27/06/24 | 0.006 | -14.29% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 07:36 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB6FNY |
| ISIN | DE000JB6FNY6 |
| Date issued | 21/11/2023 |
| Strike | 350 $ |
| Maturity | 19/07/2024 (15 Days) |
| Parity | 10 : 1 |
| Emission price | 2.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.89 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.199 € |
| Spread % | 94.76% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
